
UPcare Group is excited to announce that the U.S. Food and Drug Administration (FDA) has granted registration for UPcare's UPplus® A Capsules at 5 MAR 2021, allowing it to be manufactured and free sale in the United States.

FDA Certificate of Free Sale
"This is very good timing to get the Capsules granted market entry permit in both Australia and USA", said Acting CEO Victor HUANG, "recently UPcare Group is also actively raising funds and working with CRO company for clinic trials in preparation for prescribed medicine registration, the actual complimentary medicine products released to the market will streamline the data collection process. We have UPplus® KBD Spray approved late last year to assist , and so far feedbacks from USA consumers who used the spray are very possitive, according to our USA consultant's records, non users was infected COVID-19 after using the spray while they maintained normal daily social life. The prevetion function worked well. The newly released hardgel capsule product is even more powerful in terms of virus inhibitation, it could help people to speed up treatment and rehabitation."
UPplus® A Capsules are powerful complementary medicines combining three natural compunds of UPplus-A, UPplus-U and UPplus-P to assist people against respiratory infections. UPPLUS® A Capsules help:
Enhance/improve/promote immune defence/immunity
Decrease/reduce/relieve mild bronchial irritation
Relieve symptoms of mild upper respiratory tract infections
Decrease/reduce/relieve symptoms of common cold
Decrease/reduce/relieve cough Maintain/support lung health
Relieve symptoms of sore throat/pharyngitis
UPplus® A Capsules contains UP-A, UP-U and UP-P where the combination has been shown in preclinical laboratory studies in famous Australian P4 labs to inactivate a broad spectrum of respiratory viruses, including >99.7% of coronavirus SARS-CoV-2 (the virus that causes COVID-19) .

UPplus® A Capsules could provide stronger additional line of defence in addition to conventional PPE and vaccines for frontline workers and people in crisis environment such as public transport and aged care. UPplus formulation is patented by Apex Biotech under UPcare Group and a specific PCT patent application has been filed for its use in capsules.
Up to 8 Mar 2021, the total number of patients infected with COVID-19 in the United States has reached 29.7 million and 537,838 have died. There simply is no any registered medicine in the market yet except Remsidivir recently supported by FDA only for shortening the treatment cycle. Latest findings also suggest that the vaccines in the market are not effectively inhibiting virus infection in Upper Respiratory Tract, both Mr. Anthony Fauci and Mr. Nanshan ZHONG call for more research and development in drugs. Therefore UPcare Group hereby calls on support of UPPlus products to add on extra protection against the virues, both products will be great gifts for families and friends living in the pandemic.

Both UPplus® A Capsule and UPplus® KBD Spray are registered and approved for sale in Australia and USA, and is available for sale online, www.upcare.tech
About UPcare Group
UPCare Group Pty Ltd global biopharmaceutical company and a world leader in the development of pharmaceutical and medical products based on natural botanic combinations called UPplus® with focuses on COVID-19. UPcare has developed UPplus KBD Spray™ (an antiviral oral spray) and UPplus A Capsules™, (an antiviral capsule) for COVID-19 and other respiratory infections, which are complementary to vaccines and other preventative measures such as social distancing and PPE. Both UPplus® products are approved by both Australia and USA government authorities and registered for free sale.
As a leading company in the botanic based drug delivery, UPcare’s proprietary drug delivery platform Apex Biotech Research, which has been collaborating with the prestigious Monash Univeristy is being used to screening compounds, improve pharmaceuticals, to reduce toxicities and enhance their performance.
Comments